obicetrapib
Small moleculeexperimental
Clinical trial activity
15 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
11
Phase 3
6
Phase 4
0
Earliest trial started Feb 18, 2021 (NCT04753606)
Timeline
Indications
Studied for
- Alzheimer Disease · Phase 2
- Atherosclerosis · Phase 3
- Coronary Artery Disease · Phase 3
- Diabetes Mellitus, Type 2 · Phase 3
- Dyslipidemias · Phase 3
- Genetic Diseases, Inborn · Phase 3
- Healthy Volunteers · Phase 1
- Heart Diseases · Phase 3
- Hypercholesterolemia · Phase 3
- Hyperlipidemias · Phase 3
- Hyperlipoproteinemias · Phase 3
- Hyperlipoproteinemia Type II · Phase 3
- Lipid Metabolism · Phase 1
- Lipid Metabolism Disorders · Phase 3
- Lipid Metabolism, Inborn Errors · Phase 3
- Liver Diseases · Phase 1
- Metabolic Diseases · Phase 3
- Plaque, Atherosclerotic · Phase 3
Mechanism of action
- Cholesteryl ester transfer proteinINHIBITOR
CETP inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)N1c2ccc(C(F)(F)F)cc2[C@@H](N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2ncc(OCCCC(=O)O)cn2)C[C@H]1CC- Mol. weight
- 722.61 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3785197 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07219602 | Phase 3 | Dec 31, 2025 | NewAmsterdam Pharma |
| NCT06982508 | Phase 2 | Sep 9, 2025 | MB Clinical Research and Consulting LLC, NewAmsterdam Pharma |
| NCT06547359 | Phase 1 | Oct 1, 2024 | NewAmsterdam Pharma, Pharma Medica |
| NCT06305559 | Phase 3 | May 16, 2024 | NewAmsterdam Pharma |
| NCT06005597 | Phase 3 | Jan 31, 2024 | NewAmsterdam Pharma |
| NCT06081166 | Phase 1 | Oct 31, 2023 | NewAmsterdam Pharma, Pharma Medica |
| NCT06048302 | Phase 1 | Oct 25, 2023 | NewAmsterdam Pharma |
| NCT05972278 | Phase 1 | Sep 25, 2023 | NewAmsterdam Pharma, University of Pennsylvania |
| NCT05425745 | Phase 3 | Jul 25, 2022 | NewAmsterdam Pharma |
| NCT05421078 | Phase 2 | Jun 27, 2022 | NewAmsterdam Pharma |
| NCT05266586 | Phase 2 | Mar 9, 2022 | NewAmsterdam Pharma |
| NCT05202509 | Phase 3 | Feb 7, 2022 | NewAmsterdam Pharma |
| NCT05161715 | Phase 2 | Dec 31, 2021 | NewAmsterdam Pharma |
| NCT05142722 | Phase 3 | Dec 31, 2021 | NewAmsterdam Pharma |
| NCT04753606 | Phase 2 | Feb 18, 2021 | NewAmsterdam Pharma |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| NewAmsterdam Pharma | For profit | 15 | 15 | 3 | 2021 |
| Pharma Medica | For profit | 2 | 0 | 1 | 2023 |
| MB Clinical Research and Consulting LLC | For profit | 1 | 0 | 1 | 2025 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1